Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BS HH 002

Next Previous
Drug Profile

BS HH 002

Alternative Names: BS-HH-002; BS-HH-002.SA; HH-002

Latest Information Update: 31 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hangzhou Bensheng Pharmaceutical
  • Class Alkaloids; Antineoplastics; Harringtonines; Small molecules
  • Mechanism of Action Activating transcription factor 3 inhibitors; Activating transcription factor inhibitors; Apoptosis stimulants; Janus kinase 2 inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Polycythaemia vera; Solid tumours

Most Recent Events

  • 08 Feb 2021 Hangzhou Bensheng Pharmaceuticals and Shanghai Bensheng Pharmaceutical plans a phase I trial for Acute myeloid leukaemia (Recurrent,Refractory metastatic disease) and Myelodysplastic syndromes (Treatment-resistant) (SC) in February 2021 (NCT04743115)
  • 28 Jun 2019 No recent reports of development identified for preclinical development in Polycythaemia-vera in USA
  • 28 Jun 2019 No recent reports of development identified for preclinical development in Solid-tumours in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top